{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:38:47Z","timestamp":1784954327657,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Despite the availability of biologic and targeted synthetic disease\u2010modifying antirheumatic drugs (b\/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks. ABBV\u2010154, an antibody\u2010drug conjugate, is made up of adalimumab linked to a glucocorticoid receptor modulator. This phase 2b study evaluated the efficacy and safety of ABBV\u2010154 in patients with moderately to severely active RA receiving background methotrexate with inadequate response to at least one prior b\/tsDMARD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized 1:1:1:1:1 to subcutaneous ABBV\u2010154 40, 150, or 340 mg every other week; 340 mg every 4 weeks; or placebo. The primary endpoint was achieving 50% improvement in the American College of Rheumatology response criteria (ACR50) at week 12; secondary endpoints included achieving the ACR20 and ACR70 criteria. Treatment\u2010emergent adverse events (TEAEs) were monitored. Clinical development of ABBV\u2010154 was discontinued; the study was terminated early.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 472 patients were treated. At week 12, more patients achieved ACR50 (primary endpoint) with ABBV\u2010154 (25.5%\u201344.4% across dose groups) versus placebo (6.3%; all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). ACR20 response rates were higher in all ABBV\u2010154 treatment groups versus placebo (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Most ABBV\u2010154 groups achieved the other secondary endpoints. For all ABBV\u2010154 doses, TEAEs rates through week 12 were similar to placebo. Ten serious infection TEAEs occurred in the ABBV\u2010154 groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ABBV\u2010154 demonstrated superior efficacy over placebo in patients with RA and inadequate response to prior b\/tsDMARDs. TEAE rates in all ABBV\u2010154 arms were comparable with placebo. These findings provide useful insights into the design of new antibody\u2010drug conjugates for RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.43266","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T23:38:52Z","timestamp":1749598732000},"page":"1673-1681","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of\n                    <scp>ABBV<\/scp>\n                    \u2010154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo\u2010Controlled Trial"],"prefix":"10.1002","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin, and Deutsches Rheumaforschungszentrum  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Singhal","sequence":"additional","affiliation":[{"name":"SouthWest Arthritis Research Group  Mesquite Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Arthritis and Osteoporosis Center Altoona Center for Clinical Research  Duncansville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"Drescher","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Veszpr\u00e9m Csolnoky Ferenc County Hospital  Veszpr\u00e9m Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Metabolism, Nephrology and Rheumatology, Kochi Medical School Hospital  Nankoku Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosal\u00eda Mart\u00ednez","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Servicio de Reumatolog\u00eda, Hospital Universitario de Valme  Valme Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Anderson","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronilda","family":"D'Cunha","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihan","family":"Zhao","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"DeVogel","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Parmentier","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Christmann","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Arikan","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Amital","sequence":"additional","affiliation":[{"name":"Department of Medicine \u2018B\u2019, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel\u2010Hashomer, Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2022.03.005"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41752"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222010922"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12823"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040880"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1111-4"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102399"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab209"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-072300"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102398"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221114101"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c02099"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01174"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42415"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2229101"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:48:26Z","timestamp":1767084506000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.43266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/art.43266"],"URL":"https:\/\/doi.org\/10.1002\/art.43266","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}